TABLE 5: Incremental effectiveness by variation Maximum and Minimum Xpert with subsidies and DST-MGIT.
| Xpert with Subsidies | ||||
|---|---|---|---|---|
| Xpert | Xpert (variation) and DST-MGIT (fixed) 80.55% | |||
| Maximum | 99.00 | 18.45 | ||
| Average | 94.12 | 13.57 Incremental effectiveness | ||
| Minimum | 71.00 | Negative (-9.55) | ||
| DST-MGIT | DST-MGIT (variation) and Xpert (fixed) 94.12% | |||
| Maximum | 91.00 | 3.12 | ||
| Average | 80.55 | 13.57 Incremental effectiveness | ||
| Minimum | 65.00 | 29.12 | ||
| Xpert | Incremental cost | Test’s effectiveness | ICER | |
| Without subsidy | Xpert without subsidy less | and Standard Deviation | ||
| DST-MGIT | ||||
| US$ 175.24 | US$108.11 | Maximum 99.00 | Xpert (variation) and DST-MGIT (fixed) 80.55% | US$ 5.85 |
| Average 94.12 | US$ 7.97 | |||
| Minimum 71.00 | dominated | |||
| Maximum 91.00 | DST-MGIT (variation) and Xpert (fixed) 94.12% | US$ 34.65 | ||
| Average 80.55 | US$ 7.97 | |||
| Minimum 65.00 | US$ 3.71 | |||
Legend: DST: Drug Susceptibility Test; MGIT: BactecTMMGITTM960 System; Xpert: Xpert®MTB/RIF; ICER: incremental cost-effectiveness ratio.